.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

CONTROL, SURVIVAL IMPROVE

July 1, 2004

ImClone Systems Inc. and Bristol-Myers Squibb Co. report that the combination of Erbitux (cetuximab) injection and high-dose radiation yielded locoregional control and improved survival rate for patients with locally advanced squamous cell carcinoma of the head and neck.